Zimmer Biomet Sales Up, But Profits Squeezed by Rising Costs & M&A

Ticker: ZBH · Form: 10-Q · Filed: Nov 5, 2025 · CIK: 1136869

Sentiment: mixed

Topics: Orthopedics, Medical Devices, Earnings Report, Restructuring, Acquisitions, Debt, Healthcare, Q3 2025

Related Tickers: ZBH, SYK, JNJ

TL;DR

**ZBH is growing revenue but sacrificing short-term profits for long-term M&A-driven expansion, making it a riskier bet for immediate returns.**

AI Summary

Zimmer Biomet Holdings, Inc. reported strong net sales growth for the three and nine months ended September 30, 2025. Net sales for the three months increased by 9.7% to $2,001.4 million from $1,824.2 million in the prior year, while nine-month net sales rose 5.9% to $5,987.7 million from $5,655.4 million. Despite this revenue growth, net earnings for the three months decreased by 7.3% to $230.9 million from $249.1 million, and for the nine months, net earnings fell by 14.8% to $565.8 million from $664.3 million. This decline in net earnings was primarily driven by a significant increase in interest expense, net, which surged to $75.4 million for the quarter and $220.9 million for the nine months, up from $54.3 million and $156.1 million respectively in 2024. The company also initiated a new global restructuring program in February 2025, the '2025 Restructuring Plan,' expected to incur $85 million in pre-tax charges by the end of 2027, with $43.3 million already incurred in the first nine months of 2025. Additionally, business combination investments, net of acquired cash, dramatically increased to $1,226.3 million for the nine months ended September 30, 2025, compared to $116.3 million in the same period of 2024, indicating significant M&A activity. Diluted EPS decreased to $1.16 for the quarter and $2.84 for the nine months, down from $1.23 and $3.24 respectively.

Why It Matters

For investors, ZBH's robust sales growth, particularly in Knees and S.E.T. product categories, signals strong market demand for its core orthopedic products, which is a positive. However, the significant drop in net earnings and diluted EPS, coupled with a substantial increase in interest expense and M&A-related investments, suggests potential margin pressure and a shift towards growth through acquisition. This could impact profitability in the short term but may position the company for long-term competitive advantage against rivals like Stryker and Johnson & Johnson by expanding its product portfolio and market reach. Employees might face continued restructuring impacts, as the 2025 Restructuring Plan is ongoing, while customers could benefit from an expanded product offering.

Risk Assessment

Risk Level: medium — The risk level is medium due to declining net earnings and diluted EPS despite strong sales growth, coupled with a significant increase in long-term debt to $7,512.6 million from $5,341.6 million at December 31, 2024. This debt increase, alongside substantial business combination investments of $1,226.3 million, indicates aggressive M&A activity that could strain financial resources and integration capabilities, impacting future profitability.

Analyst Insight

Investors should closely monitor Zimmer Biomet's integration of recent acquisitions and the realization of synergies from its restructuring plans. While sales growth is positive, the declining net earnings and increased debt warrant caution; consider holding or initiating a smaller position until there's clearer evidence of improved profitability and successful debt management.

Financial Highlights

revenue
$5,987.7M
total Debt
$7,512.6M
net Income
$565.8M
eps
$2.84
revenue Growth
+5.9%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Sales$2,001.4M+9.7%
Total Net Sales$5,987.7M+5.9%

Key Numbers

Key Players & Entities

FAQ

What were Zimmer Biomet's net sales for the third quarter of 2025?

Zimmer Biomet Holdings, Inc. reported net sales of $2,001.4 million for the three months ended September 30, 2025, an increase of 9.7% compared to $1,824.2 million in the same period of 2024.

How did Zimmer Biomet's net earnings change in Q3 2025?

Net earnings for Zimmer Biomet Holdings, Inc. decreased by 7.3% to $230.9 million for the three months ended September 30, 2025, down from $249.1 million in the prior year's third quarter.

What was the diluted EPS for Zimmer Biomet in the third quarter of 2025?

Zimmer Biomet's diluted earnings per common share (EPS) for the three months ended September 30, 2025, was $1.16, a decrease from $1.23 reported in the third quarter of 2024.

What is the '2025 Restructuring Plan' for Zimmer Biomet?

The '2025 Restructuring Plan' is a new global program approved in February 2025 by Zimmer Biomet's management, aimed at reducing costs and transforming operations. It is expected to incur approximately $85 million in total pre-tax restructuring charges by the end of 2027.

How much has Zimmer Biomet spent on business combination investments in the first nine months of 2025?

For the nine months ended September 30, 2025, Zimmer Biomet Holdings, Inc. spent $1,226.3 million on business combination investments, net of acquired cash, a significant increase from $116.3 million in the same period of 2024.

What are the primary reasons for the decline in Zimmer Biomet's net earnings?

The decline in Zimmer Biomet's net earnings is primarily attributed to a substantial increase in interest expense, net, which rose to $75.4 million for the quarter and $220.9 million for the nine months, and increased operating expenses including intangible asset amortization and selling, general and administrative costs.

What is Zimmer Biomet's long-term debt as of September 30, 2025?

As of September 30, 2025, Zimmer Biomet Holdings, Inc.'s long-term debt stood at $7,512.6 million, an increase from $5,341.6 million reported on December 31, 2024.

Which product categories contributed most to Zimmer Biomet's net sales in Q3 2025?

In Q3 2025, Zimmer Biomet's Knees product category generated $792.4 million in sales, while S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) contributed $541.5 million, showing strong performance in these segments.

What are the potential risks associated with Zimmer Biomet's current financial strategy?

The current financial strategy, marked by increased long-term debt and significant business combination investments, carries risks related to successful integration of acquired entities, potential overleveraging, and the ability to generate sufficient returns to offset higher interest expenses and maintain profitability.

How does Zimmer Biomet's cash position look at the end of Q3 2025?

Zimmer Biomet Holdings, Inc. reported cash and cash equivalents of $1,292.7 million as of September 30, 2025, a substantial increase from $525.5 million at the beginning of the year, primarily driven by proceeds from senior notes.

Risk Factors

Industry Context

The medical device industry, particularly in orthopedics, is characterized by intense competition, rapid technological advancements, and significant regulatory oversight. Companies like Zimmer Biomet must continuously innovate and invest in R&D to maintain market share and develop next-generation products. Consolidation through mergers and acquisitions is also a common strategy to expand product portfolios and geographic reach.

Regulatory Implications

As a global medical device manufacturer, ZBH faces stringent regulatory scrutiny from agencies like the FDA and international bodies. Compliance with evolving regulations, product approval processes, and post-market surveillance are critical. Non-compliance or product issues can lead to costly recalls, fines, and significant damage to reputation and market access.

What Investors Should Do

  1. Monitor the impact of the '2025 Restructuring Plan' on future earnings and operational efficiency.
  2. Analyze the strategic rationale and integration success of recent business combination investments.
  3. Assess the company's ability to manage increased debt levels and interest expenses.
  4. Evaluate the sustainability of revenue growth in light of declining net earnings and EPS.

Key Dates

Glossary

Business Combination Investments
Investments made by the company to acquire or merge with other businesses. 'Net of acquired cash' means the cash held by the acquired company has been subtracted from the investment cost. (A significant increase indicates substantial M&A activity, which can drive growth but also carries integration risks and financial implications.)
2025 Restructuring Plan
A formal plan initiated by the company to reorganize its operations, which typically involves costs associated with workforce reductions, facility consolidations, or other efficiency improvements. (The associated pre-tax charges directly impact the company's net earnings and profitability.)
Diluted EPS
Earnings per share calculated by dividing net income by the weighted-average number of outstanding common shares, including the dilutive effect of stock options and convertible securities. (A key metric for investors to assess profitability on a per-share basis; a decrease indicates lower profitability per share.)

Year-Over-Year Comparison

Compared to the prior year, Zimmer Biomet Holdings, Inc. has demonstrated robust revenue growth, with net sales increasing by 9.7% for the quarter and 5.9% for the nine months. However, this top-line improvement has not translated to the bottom line, as net earnings have declined by 7.3% and 14.8% respectively. This divergence is primarily attributed to a substantial increase in interest expense and costs associated with a new restructuring program. Additionally, the company has significantly ramped up its M&A activity, as evidenced by the surge in business combination investments, and has seen a notable increase in its long-term debt.

Filing Stats: 4,463 words · 18 min read · ~15 pages · Grade level 6.5 · Accepted 2025-11-05 16:06:05

Key Financial Figures

Filing Documents

- Financial Information

Part I - Financial Information Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Statements of Earnings for the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 7 Notes to Interim Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 37

- Other Information

Part II - Other Information Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 39

– Financ ial Information

Part I – Financ ial Information

Financ ial Statements

Item 1. Financ ial Statements ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (in millions, except per share amounts, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Net Sales $ 2,001.4 $ 1,824.2 $ 5,987.7 $ 5,655.4 Cost of products sold , excluding intangible asset amortization 559.3 538.6 1,701.3 1,604.5 Intangible asset amortization 176.5 148.2 488.2 434.3 Research and development 115.9 111.6 339.8 328.9 Selling, general and administrative 811.4 709.7 2,384.9 2,182.9 Restructuring and other cost reduction initiatives 21.4 32.2 74.9 198.1 Acquisition, integration, divestiture and related ( 34.4 ) 4.4 55.0 9.9 Operating expenses 1,650.1 1,544.7 5,044.1 4,758.6 Operating Profit 351.3 279.5 943.6 896.7 Other income, net 3.3 5.1 10.1 7.0 Interest expense, net ( 75.4 ) ( 54.3 ) ( 220.9 ) ( 156.1 ) Earnings before income taxes 279.2 230.3 732.8 747.6 Provision (benefit) for income taxes 48.0 ( 18.9 ) 165.6 82.5 Net Earnings 231.2 249.2 567.2 665.1 Less: Net earnings attributable to noncontrolling interest 0.3 0.2 1.4 0.8 Net Earnings of Zimmer Biomet Holdings, Inc. $ 230.9 $ 249.1 $ 565.8 $ 664.3 Earnings Per Common Share Basic $ 1.17 $ 1.23 $ 2.85 $ 3.25 Diluted $ 1.16 $ 1.23 $ 2.84 $ 3.24 Weighted Average Common Shares Outstanding Basic 198.1 202.3 198.3 204.4 Diluted 198.8 203.0 199.0 205.2 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEM ENTS OF COMPREHENSIVE INCOME (in millions, unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing